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ORIGINAL ARTICLE
Indication for CDKN2A-mutation analysis in familial
pancreatic cancer families without melanomas
Femme Harinck,1 Irma Kluijt,2 Nienke van der Stoep,3 Rogier A Oldenburg,4
Anja Wagner,4 Cora M Aalfs,5 Rolf H Sijmons,6 Jan-Werner Poley,1
Ernst J Kuipers,1,7 Paul Fockens,8 Theo A M van Os,5 Marco J Bruno1
ABSTRACT
Background CDKN2A-mutation carriers run a high risk of
developing melanomas and have an increased risk of
developing pancreatic cancer (PC). Familial PC (FPC)
patients with a personal history or family history of
melanomas are therefore offered CDKN2A-mutation
analysis. In contrast, CDKN2A testing in FPC families
without a history of melanomas is not generally
recommended. The aim of this study was to evaluate the
frequency of CDKN2A-mutations in FPC families without
melanomas.
Methods Data were gathered from PC family registers.
FPC families were defined as families with clustering of
PC without meeting diagnostic criteria of familial
cutaneous malignant melanoma (familial CMM) or other
inherited cancer syndromes. Blood samples were
obtained for DNA isolation from PC patients or first
degree relatives and analysed for CDKN2A-mutations.
Results Among 40 FPC families, DNA analyses were
carried out in 28 families (70%), leading to identification
of CDKN2A-mutations in six families (21%). None of the
CDKN2A-mutation-positive families fulfilled the
diagnostic criteria for familial CMM and in three CDKN2A
families no melanomas were observed. Two CDKN2A-
mutations were found; the Dutch founder mutation p16-
Leiden (c.225_243del, p.Ala76fs) and the c.19_23dup,
p.Ser8fs-mutation. After disclosure of the CDKN2A-
mutation in one of the families, a curable melanoma was
diagnosed at dermatological surveillance in a 17-year-old
family member.
Conclusion CDKN2A-mutation can be found in
a considerable proportion of families with FPC. CDKN2A-
mutation analysis should therefore be included in genetic
testing in FPC families, even in the absence of reported
melanomas. This strategy will enhance the recognition of
individuals at risk for PC and facilitate the early detection
of melanomas.
INTRODUCTION
Approximately 10% of all pancreatic cancer (PC) cases
occur in a background of familial clustering.1 In about
20% of these cases the underlying gene mutation is
recognised.1 One such inherited cancer syndrome
with a known increased risk for PC is familial cuta-
neous malignant melanoma (familial CMM), referred
to in the past as the familial atypical multiple mole
melanoma syndrome (OMIM 155600).2e5
This syndrome is characterised by the familial
occurrence of melanomas5 and inherits as an
autosomal dominant trait. Germ-line mutations in
CDKN2A have been found in at least a quarter of all
melanoma prone families.6 7
In addition to an increased risk of developing
melanomas, CDKN2A-mutation carriers are also at
risk of other types of cancer, particularly PC.2e4
Previous studies have shown that the risk of
developing PC among CDKN2A carriers may be 50
times greater than in the general population.3
Therefore, families with any combination of
PC and melanomas should be offered CDKN2A
analysis.8e14 However, CDKN2A analysis is not
recommended in families with a clustering of PC
but without melanomas.10
The aim of this study was to evaluate the
frequency of CDKN2A-mutations in familial PC
(FPC) families without melanomas.
MATERIALS AND METHODS
Patients and families
We conducted a retrospective cohort study. Data
were gathered from PC family registries from four
Dutch clinical genetic centres (Academic Medical
Center Amsterdam, Erasmus MC-University
Medical Center Rotterdam, University Medical
Center Groningen and the Netherland Cancer
Institute-Antoni van Leeuwenhoek Hospital). The
total number of PC families was 70. Based on their
phenotype, PC families were divided into FPC
families (n¼40) and syndromic PC families (n¼30).
FPC families were deﬁned as families with clustering
of PC ($2 ﬁrst degree relatives (FDR), $3 relatives
(FDR or second degree relatives (SDR)) or two SDR
relatives, one <50 years at diagnosis) and not meeting
diagnostic criteria of known inherited cancer
syndromes (listed below).10 Syndromic PC families
were deﬁned as families with a known inherited cancer
syndrome predisposing them to PC (including familial
CMM, Peutz-Jeghers, Lynch, Li-Fraumeni and heredi-
tary breast and ovarian cancer syndromes). The diag-
nosis of familial CMM was made based on the Dutch
clinical criteria of familial atypical multiple mole
melanomas in either $2 affected FDR or $3 affected
relatives (FDR and/or SDR).15 The total number of
familial CMM families within the cohort of syndromic
PC families was 16 (53%).
In this study, we included only the FPC families
and analysed whether DNA-mutation analysis for
CDKN2A/CDK4 was performed, and if so what the
outcome of this mutation analysis was. DNA,
either from blood samples or available parafﬁn
embedded tumour samples, originated from indi-
viduals affected with PC or, in families without
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available DNA from affected individuals, from healthy FDRs.
For each family, a complete three-generation pedigree was made.
Clinical diagnoses reported by patients and family members
were veriﬁed by a review of medical and pathological records,
and by revision of histological slides whenever available. At the
time of genetic counselling, patients or their family members
had given written informed consent to use the DNA results for
future research projects.
All individuals from CDKN2Aemutation-positive families
were advised to undergo dermatological examination to detect
dysplastic nevi and/or melanoma.
CDKN2A/CDK4-mutation analysis
Direct sequencing of all CDKN2A exons and CDK4 exon 2 was
performed on samples from the index cases, and subsequently
on relatives of mutation-positive cases. In brief, all exons with
ﬂanking intronic regions were ampliﬁed by PCR using the
following primers: CDKN2A-EX1BF 59-GTGCGTGGGTCCCA
GTCT-39, CDKN2A-EX1BR 59-TAGCCTGGGCTAGAGACG
AA-39 (Ta¼578C), CDKN2A-EX1AF 59-TTCGCTAAGTGCTC
GGAGTT-39, CDKN2A-EX1AR 59-GAGAATCGAAGCGCTA-
CCT-39 (Ta¼578C), CDKN2A-EX2F 59-GGAAATTGGAAACTG-
GAAGC-39, CDKN2A-EX2R 59-GCTGAACTTTCTGTGCTGGA
AAAATG-39 (Ta¼558C), CDKN2A-EX3F 59-GCAGTGGACTA-
GCTGCTGGA-39, CDKN2A-EX3R 59-TTTACGGTAGTGGGG-
GAAGG-39 (Ta¼578C) and CDK4-EX2F 59-TTGTTGCTGCAG
GCTCATAC-39, CDK4-EX2R 59-TCAGGGTCCCCACTTCTC
TA 39 (Ta¼578C). All primers were ﬂanked with respectively
m13forward or reverse tags to allow direct sequencing. PCR
reactions were carried out using GoTaq DNA Polymerase
(Promega, Benelux b.v.) based on the standard protocol at
annealing temperature (Ta) as indicated at the primers. Subse-
quently, the sequence PCR products were analysed on an
ABI3730 sequencer using BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, California,
USA) and genotypes were assigned using SeqScape software
(Applied Biosystems). The reference sequences for CDKN2A and
for CDK4 respectively with GenBank accession numbers
NT_008413 v17 and NC_000012 v10 were used to analyse the
sequence results and all detected variants were described
according to the HGVS nomenclature recommendations.
CNV analysis of CDKN2A was performed for all samples by
Multiplex Ligation-dependent Probe Ampliﬁcation using the
MRC-Holland probe-mix ME024-A1 (MRC-Holland, Amsterdam,
Netherlands) as indicated by the manufacturer. CNV data for the
CDKN2A region speciﬁc probes were analysed using GeneMarker
software package (SoftGenetics, Pennsylvania, USA).
Data analyses
Continuous variables are presented as mean (SD) or median
(IQR), where appropriate. Continuous variables were compared
using the t test or the ManneWhitney test. Categorical vari-
ables were compared using the c2 or Fisher ’s exact test. All
analyses were conducted using the Statistical Package for the
Social Sciences (V.17.0; SPSS Institute). A two-sided p value
<0.05 was considered to be statistically signiﬁcant.
RESULTS
In our series of 40 FPC families, DNA analyses were carried out in
28 families (70%). Of the remaining 12 families, DNA was not
available. Twenty-seven of the 28 analysed families (96%) were
of Caucasian descent and one family (3.6%) was of Indonesian
descent (Maluku Islands). These 28 FPC families had a total of
74 affected patients with PC. In 14 families (50%) two family
members were diagnosed with PC, in 12 families (43%) three
family members were diagnosed with PC, in one family (3.6%)
four family members were diagnosed with PC and in one family
(3.6%) seven family members were diagnosed with PC. Of the 74
PC cases, 41 (55%) were male subjects. The mean age of diag-
nosis of PC was 59.0 years (range 30e84 years, SD 12.3). Nine
patients (12%) were younger than 45 at the time of diagnosis. In
addition to the PC cases, 24 families (86%) were affected by other
types of cancer. Four families (14%) were affected by melanomas,
and nine families (32%) were affected by breast cancer.
In 21 FPC families (75%), DNAwas available from affected PC
cases, isolated from blood samples in 19 families and from PC
tumour tissue in two families. In the remaining families, DNA
analyses were carried out in DNA of healthy FDR (six families;
mean number of FDR tested 1.7, range 1e3) or suspected carriers
(one family) because of their position in the pedigree.
DNA analyses of mutations in CDKN2A/CDK4 led to the
identiﬁcation of a causal genetic factor in six (21.4%) FPC
families. In three (50%) of these CDKN2A-mutation-positive
FPC families, no melanomas and/or dysplastic nevi had been
reported at the time of DNA analyses. In the other three
CDKN2A-mutation-positive FPC families, two had one family
member diagnosed with melanoma and in the third family two
second degree members were diagnosed with melanoma.
Two different CDKN2A-mutations were found, the Dutch
founder mutation p16-Leiden (c.225_243del, p.Ala76fs) and the
c.19_23dup.p.Ser8fs-mutation. The p16-Leiden-mutation was
found in all three melanoma-positive (100%) families and in two
of the melanoma-negative (67%) families.
Table 1A shows the characteristics of the CDKN2A-mutation-
positive FPC families without melanomas; supplementary
ﬁgures A to C display the pedigrees. These three families
included a total of eight PC cases of whom ﬁve were male
subjects (63%) and the mean age at the time of diagnosis was
51.5 years (SD 9.2). Two patients (25%) were younger than
45 years at the time of diagnosis. The Dutch founder mutation
was found in two Caucasian families. The c.19_23dup.p.Ser8fs-
mutation was found in the family of Indonesian descent.
The CDKN2A-mutation-positive FPC families without mela-
noma (table 1A) and with melanomas (table 1B) included a total
of 19 PC cases of whom 10 were male subjects (53%) and the
mean age at the time of diagnosis was 55.7 (SD 10.2). These
characteristics were not statistically signiﬁcantly different from
the PC cases of the other FPC families: mean age at the time of
diagnosis was 60.1 (SD 12.8), 56% were male persons.
DISCUSSION
In six out of 28 FPC families tested, we identiﬁed a CDKN2A-
mutation (21%), in three of whom (50%) no melanomas and/or
dysplastic nevi had been reported at the time of DNA analysis. If
the current recommendation would have been followed to test only
for CDKN2A-mutations in FPC families with at least one mela-
noma case, these three families would have gone unnoticed.10 This
recommendation is based on three previous studies on the role of
CDKN2A-mutations in FPC families, which failed to identify
CDKN2A-mutations in non-melanoma FPC families9 12 13 (table 2).
Recently, the prevalence of CDKN2A-mutations in a large series of
unselected PC cases was studied and this turned out to be low
(0.6%).16 A subanalysis of this series in which only FPC cases were
included showed CDKN2A-mutations in 3.3% of cases. The
discrepancy between these and our series is not readily explained,
although the method of patient selection between our series
(gathered from PC family registries) and the latter large series
(unselected PC cases) may account for part of the discrepancy. It
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does not seem likely that the differences in results can be explained
by the type of CDKN2A-mutations that we found. The Dutch
founder mutation p16-Leiden, which two of our CDKN2A-
mutaion-positive non-melanoma FPC families carried, is a well-
researched mutation; the phenotype of its carriers is not restricted to
clustering of PC only.3 Although, a part of the differences might be
explained by the founder role of this mutation. The third CDKN2A-
mutation-positive non-melanoma FPC family carried a c.19_23dup.
p.Ser8fs-mutation. To our knowledge, this is a new mutation that
has not been previously reported. The frame shift that is caused by
this mutation causes a stop-codon. Based on the results of this one
family, it is too early to claim that this speciﬁc mutation causes
a phenotype without melanomas. The family in whom the
c.19_23dup.p.Ser8fs-mutation was detected is of Indonesian descent
and their darker-skinned complexion might have offered them
added protection from developing melanomas. It is well known that
the risk of developing melanoma is higher in fair-skinned people,
especially those with blond or red hair and who sunburn and freckle
easily than in people with darker complexions.17 The two families
with the Dutch founder mutation were Caucasian.
Differences in lifestyle may also explain some of the difference
between the results of earlier studies and our series. For example,
it is well known that cigarette smoking is associated with an
increased risk of PC.18 Unfortunately, we lack detailed infor-
mation about smoking status. We therefore cannot exclude the
possibility that in our series the PC affected family members of
non-melanoma CDKN2A-mutation-positive families smoked
more than affected individuals in the previously published
studies which also did not report on smoking status.
Another limitation of this current series is that in some
families affected relatives were unavailable for DNA testing and,
instead, unaffected FDRs were tested. A negative genetic test
result in such cases does not exclude the presence of a pathoge-
netic mutation unless a speciﬁc genetic mutation is been found
in another relative. This may have caused an underestimation of
the prevalence of CDKN2A/CDK4 in this current study.
We were able to collect detailed information on the family
history of all FPC families in whomDNA analyses were carried out.
In addition, patients not known with any skin lesions before they
were genetically tested were seen by a dermatologist, minimising
the chance that we missed a diagnosis of melanoma or dysplastic
nevi negligible. Since in both family B and family C some family
members died of cancer of unknown origin, we cannot state with
100% certainty that none of these individuals died of melanoma.
The three non-melanoma FPC families in which a CDKN2A-
mutation was found were of moderate to large size. It is
therefore less likely that melanoma or dysplastic nevi were not
observed because of a low a priori change based on numbers and
RR. Interestingly, during dermatological follow-up of one of our
CDKN2A-positive FPC families we detected an early stage
melanoma in a 17-year-old female family member. A year after
resection of a 5-mm superﬁcial spreading melanoma (Breslow
0.8 mm), this patient is disease-free.
Among the 28 families in which CDKN2A-mutation was
performed, four families (14%) were affected by $1 melanoma
(s). It is of interest that in three (75%) of these melanoma-
positive families, a mutation in CDKN2A was found. These
ﬁndings are in line with previous reports showing that
CDKN2A-mutations are frequently found in families affected
by both PC and melanomas.8 9 The prevalence of CDKN2A-
mutations in the remaining melanoma-negative FPC families
was 12%.
Table 1 Characteristics of CDKN2A-positive FPC families without melanomas (A) and CDKN2A-positive
FPC families with melanomas not fulfilling diagnostic criteria of familial CMM (B)
No. of family members




melanoma Other tumour types* Type of mutation
A
1 3/_48, _55, _67
(supplementary figure A)
0 Lung cancer n¼1 c.19_23dup.p.Ser8fs
2 3/_39, \41, \52
(supplementary figure B)
0 Cancer unknown origin n¼2 c.225_243del, p.Ala76fs
3 2/\51, _59
(supplementary figure C)
0y Basal cell carcinoma n¼1 c.225_243del, p.Ala76fs
B
4 2/_50, \67 1 Pharyngeal cancer n¼1z
Gastric cancer n¼1z
c.225_243del, p.Ala76fs
5 2/_62, _73 1 No c.225_243del, p.Ala76fs
6 7/\50, _50, _51, \59,
\65, \74, \76
2 Prostate cancer n¼1
Thyroid cancer n¼1
c.225_243del, p.Ala76fs
*Other associated tumour types in family.
yAfter disclosure of the CDKN2A-mutation in this family, a melanoma was diagnosed at dermatological surveillance in a 17-year-old
female family member.
zSame patient.
CMM, cutaneous malignant melanoma; FPC, familial PC; PC, pancreatic cancer.







Slater et al13 56 FPC families No e e
Bartsch et al9 18 FPC families No e e
Moskaluk et al12 21 FPC families Yes c.457 G>T Mel-PC family*


















*Family affected by PC and melanoma but that does not fulfil the diagnostic criteria of
familial cutaneous malignant melanoma.
yAfter disclosure of the CDKN2A mutation, a melanoma was diagnosed in this family.
FPC, familial PC; PC, pancreatic cancer.
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A number of previous reports have shown an indication for
BRCA2-mutation analysis in FPC families that did not meet the
criteria of familial breast and ovarian cancer.19e21 In a similar
way, our ﬁndings emphasise the need to include CDKN2A-
mutation analysis in genetic testing for FPC families, even in the
absence of reported melanomas. It will help to better identity
those at risk of developing PC and/or melanoma.
Surveillance of individuals at a high risk of malignant mela-
nomas has proved to lead to early detection of melanomas and
will consequently have a favourable effect in prognosis.22e24
Surveillance of individuals at high risk of PC is emerging and
may lead to an improvement of prognosis and a decline in PC
incidence.25e30
In conclusion, the results of this series show that CDKN2A-
mutation can be found in a considerable proportion of families with
FPC. CDKN2A-mutation analysis should therefore be included in
genetic testing in FPC families, even in the absence of reported
melanomas. This strategy will enhance the recognition of individ-
uals at risk for PC and facilitate the early detection of melanomas.
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